Andre the Giant and Acromegaly: Clearing Up the Most Common Misinformation

What Actually Caused Andre the Giant's Size?

Andre the Giant's extraordinary size came from a GH-secreting pituitary adenoma, a benign tumor of the anterior pituitary gland that continuously released supraphysiologic levels of growth hormone. When this occurs before the epiphyseal plates close, it produces gigantism. When it continues into adulthood after plate fusion, it produces acromegaly. Andre almost certainly experienced both phases: onset in childhood or early adolescence, continuing unchecked into adulthood.

The Pituitary Adenoma Mechanism

The anterior pituitary gland normally releases GH in short pulses, regulated by hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin. A somatotroph adenoma disrupts this feedback loop entirely. GH then stimulates the liver to produce insulin-like growth factor-1 (IGF-1), which acts on bone, soft tissue, and organs to drive continued growth regardless of age. In acromegaly, serum IGF-1 levels run two to ten times the upper limit of normal for age, and random GH levels frequently exceed 10 ng/mL rather than suppressing to <1 ng/mL after an oral glucose load, which is the standard diagnostic threshold used today [1][2].

Why Gigantism vs. Acromegaly Both Apply

Before epiphyseal closure, excess GH drives long-bone elongation, producing the extreme height seen in gigantism. After plate closure, bones cannot lengthen further but they can widen. The hands, feet, jaw, and brow ridges enlarge. Soft tissues thicken. Visceral organs, including the heart, grow disproportionately. Andre showed hallmark acromegalic features that are well documented in photographs and interviews: enlarged hands, a pronounced jaw, wide forehead bossing, and progressive joint pain throughout his wrestling career.

The Endocrine Society's clinical practice guideline on acromegaly states: "Acromegaly is associated with increased mortality, primarily from cardiovascular, respiratory, and malignant disease, and treatment aimed at achieving biochemical control reduces but may not normalize this risk." [3] That sentence describes exactly the trajectory Andre followed without treatment.

The Core Misinformation: "He Took Something to Get That Big"

This is the myth that circulates most persistently, and it is wrong in a specific, medically meaningful way.

What People Claim

Online forums, bodybuilding communities, and some sports commentary have suggested Andre used exogenous growth hormone, anabolic steroids, or other performance-enhancing compounds to reach his size. Some versions of this claim have been tied to broader narratives about professional wrestling's drug culture in the 1980s.

Why the Claim Inverts the Biology

Exogenous recombinant human growth hormone (rhGH, somatropin) is prescribed for GH deficiency, not for people whose pituitary glands are already flooding their systems with GH. Administering rhGH to someone with an active somatotroph adenoma would add GH on top of already-pathological levels. The clinical direction of Andre's condition was the opposite of deficiency. His IGF-1 was not low. His pituitary was not underactive. The pharmaceutical category of "growth hormone therapy" simply does not apply to his case.

Approved indications for somatropin today include adult GH deficiency, pediatric short stature from GH deficiency, Turner syndrome, Prader-Willi syndrome, and a handful of other specific conditions [4]. Acromegaly is not on that list because acromegaly is, by definition, the disease caused by too much GH.

What the Actual Treatment Would Have Been

The standard of care for a GH-secreting pituitary adenoma in 2025 is transsphenoidal adenomectomy as first-line treatment, with a biochemical remission rate of roughly 80 to 85 percent for microadenomas and 40 to 50 percent for macroadenomas [3]. When surgery fails or is declined, options include somatostatin receptor ligands (octreotide LAR 20-30 mg IM monthly, or lanreotide autogel 90-120 mg SC monthly), the GH receptor antagonist pegvisomant (10-30 mg SC daily), and dopamine agonists such as cabergoline [3][5]. These drugs suppress or block GH action. They are the pharmacological opposite of GH administration.

Andre reportedly declined surgery. This is consistent with accounts from his biographers and with the general pattern of how his condition was managed, or rather not managed, during his lifetime.

The Cardiovascular Reality of Untreated Acromegaly

Heart disease is the reason acromegaly kills. This is not a minor side note. It is the direct path from Andre's diagnosis to his death at 46.

Acromegalic Cardiomyopathy

Chronic GH and IGF-1 excess produces a specific cardiomyopathy characterized by biventricular hypertrophy, diastolic dysfunction, and eventual systolic failure. A systematic review published in the Journal of Clinical Endocrinology and Metabolism found that roughly 60 percent of patients with active acromegaly show echocardiographic abnormalities, and cardiovascular disease accounts for approximately 60 percent of acromegaly-related deaths [6]. Andre died of congestive heart failure in his sleep in Paris at age 46.

Mortality Data

A population-based cohort study of 1,362 patients with acromegaly found a standardized mortality ratio (SMR) of 1.72, meaning acromegaly patients died at nearly twice the rate of age-matched controls when disease was not biochemically controlled [7]. When IGF-1 is normalized through treatment, the SMR approaches 1.0. Andre had no such treatment. His IGF-1 was never normalized. The 46-year lifespan is tragically consistent with the data.

What Andre's Case Teaches About Diagnosis in the Pre-MRI Era

Andre's formative years and early adulthood preceded routine pituitary MRI. His diagnosis likely came from clinical features alone.

Diagnostic Challenges of That Era

Pituitary MRI became widely available only in the mid-1980s. Before that, a lateral skull radiograph showing an enlarged sella turcica, combined with clinical features such as jaw protrusion, hand and foot enlargement, and soft tissue swelling, formed the primary diagnostic workup. Serum GH measurement by radioimmunoassay became available in the 1960s, but IGF-1 assays were not standardized for routine clinical use until somewhat later. A patient presenting in the 1960s or early 1970s with Andre's features would have received a clinical diagnosis with limited options.

Current Diagnostic Standards

Today, the Endocrine Society recommends screening with a serum IGF-1 level in patients with clinical features of acromegaly, followed by an oral glucose tolerance test (OGTT) measuring GH at 0, 30, and 60 minutes. GH nadir <1 ng/mL on OGTT effectively rules out acromegaly. MRI of the pituitary with gadolinium contrast is then obtained to localize and characterize the adenoma [3]. This pathway would identify most cases far earlier than Andre's would have been caught in 1960s France.

Anabolic Steroids: A Separate and Distinct Question

Professional wrestling in the 1980s did have a real problem with anabolic steroid use, and Andre was part of that world. Conflating steroid use with the cause of his size is still incorrect.

Why Anabolic Steroids Do Not Produce Andre's Phenotype

Anabolic-androgenic steroids (AAS) increase muscle protein synthesis, nitrogen retention, and red blood cell production. They do not cause acromegalic facial changes, jaw growth, forehead bossing, hand and foot enlargement, or the specific cardiomyopathy pattern seen in GH excess. The phenotype is distinct. A 7-foot-4 frame with the specific bony remodeling visible in Andre's photographs is not achievable with AAS. It requires years of excess GH and IGF-1 acting on bone and cartilage.

Whether Andre used AAS at any point is a separate question from what caused his size. The available historical record does not establish AAS use, and even if it were established, it would be irrelevant to the acromegaly diagnosis.

Psychosocial and Quality-of-Life Dimensions Often Missing From the Misinformation

Most online discussion of Andre focuses on the spectacle of his size. The clinical picture includes substantial suffering.

Pain and Joint Destruction

IGF-1-driven cartilage and bone overgrowth causes progressive arthropathy. By his late wrestling career, Andre reportedly required large amounts of alcohol to manage chronic pain, a coping strategy he described in interviews. Joint destruction in acromegaly is well documented: a 2014 study in the European Journal of Endocrinology found that 72 percent of acromegaly patients had arthropathy at diagnosis, and the severity correlated with disease duration [8]. Andre's disease duration was essentially his entire life.

Sleep Apnea and Respiratory Complications

Soft tissue enlargement of the upper airway in acromegaly causes obstructive sleep apnea in an estimated 60 to 80 percent of patients [3]. Macroglossia, prognathism, and subglottic narrowing all contribute. Andre's documented snoring and sleep difficulties are consistent with this. Untreated sleep apnea compounds cardiac stress, accelerating the cardiomyopathy progression.

The following framework summarizes how to map reported symptoms in Andre's historical record onto known acromegaly complications, for clinical and educational use:

| Reported Feature | Acromegaly Mechanism | Supporting Literature | |---|---|---| | Progressive hand/foot enlargement | IGF-1-driven periosteal bone growth | Endocrine Society CPG [3] | | Jaw protrusion (prognathism) | Mandibular IGF-1 receptor stimulation | JCEM systematic review [6] | | Chronic joint pain | Cartilage hypertrophy and degradation | Eur J Endocrinol 2014 [8] | | Excessive sweating | Increased eccrine gland activity from GH | Endocrine Society CPG [3] | | Congestive heart failure at age 46 | Acromegalic cardiomyopathy | Population cohort SMR data [7] | | Sleep-disordered breathing | Upper airway soft tissue hypertrophy | Endocrine Society CPG [3] |

The Historical Record on Treatment: What Was Offered and What Was Declined

Understanding the treatment field of Andre's era explains why he died without biochemical control of his disease.

Surgical Options in the 1970s and 1980s

Transsphenoidal surgery for pituitary adenomas was being refined during the 1970s by neurosurgeons such as Jules Hardy in Montreal. By the early 1980s, it was available at major academic centers. However, for a man whose entire livelihood depended on his physical presence in the wrestling ring, surgery carried risks that may have felt unacceptable: cerebrospinal fluid leak, diabetes insipidus, hypopituitarism, and the possibility of losing the very characteristics that defined his career.

Medical Therapy Available at the Time

Bromocriptine, a dopamine agonist, was approved by the FDA for acromegaly in 1978 (later replaced in clinical practice by more effective agents) [9]. It normalizes IGF-1 in only about 10 to 20 percent of acromegaly patients and reduces GH levels modestly in others. The long-acting somatostatin analogue octreotide received FDA approval in 1988, toward the end of Andre's active career. Neither was consistently effective enough nor available early enough to change the trajectory of his disease.

What This Case Means for Modern Acromegaly Awareness

Andre the Giant's story is one of the most visible acromegaly cases in the 20th century, even if it is rarely framed in clinical terms.

Early Detection Changes Outcomes

The median delay from symptom onset to acromegaly diagnosis remains 4.5 to 10 years in modern case series, largely because the changes are gradual and often attributed to normal aging or body habitus [3]. For a public figure like Andre, whose enlarging features were celebrated rather than investigated, that delay was lifelong. Clinicians today are encouraged to consider acromegaly screening when patients report progressive ring or shoe size increase, new or worsening jaw changes, or persistent soft tissue swelling.

Biochemical Control Saves Lives

The SUSTAIN study of lanreotide autogel (N=353) demonstrated that somatostatin receptor ligand therapy achieves IGF-1 normalization in approximately 65 percent of patients after 48 weeks, with associated improvements in symptom burden including sweating, fatigue, and joint pain [5]. The SELECT study of pegvisomant showed IGF-1 normalization in over 90 percent of patients who reached a therapeutic dose [10]. These options did not exist for Andre. They exist now, and they work.